The firms will use nFerence's Agentic AI platform to analyze real-world treatment patterns in 700 patients' charts and inform personalized care.

The tool analyzes results from standard tests of organ function, tumor burden, and inflammation to predict whether lymphoma patients will respond to treatment.

A federal district court had ruled in favor of HHS, restricting Vertex's ability to provide fertility preservation services to Medicaid patients.

NEW YORK – Cardiff Oncology on Tuesday said it has completed enrolling patients with advanced RAS-mutated colorectal cancer in a Phase II trial testing the activity of its PLK1 inhibitor onvansertib ...

Ayrmid has not obtained the necessary financing to support its unsolicited, non-binding written proposal to purchase the company, Bluebird said.

Databricks will contribute data engineering and AI expertise to support the development of Tevogen's PredicTcell technology.

NEW YORK – InnoCare Pharma said on Wednesday that China's National Medical Products Administration (NMPA) accepted a new drug application (NDA) seeking approval for its pan-TRK inhibitor ...

NEW YORK – The European Commission (EC) on Tuesday authorized Biogen and Eisai's anti-amyloid Alzheimer's disease drug Leqembi (lecanemab) as a treatment for early-stage Alzheimer's disease patients ...

On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 ...